Zimbabwe has declined a substantial American healthcare agreement worth $367m (£272m) spanning five years over Washington's demand for sensitive biological samples.
This move became public following a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later stated that the United States was seeking genetic material for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from future medical innovations.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further talks to reach a agreement agreeable to both sides so the nation's critical HIV treatment initiative can be sustained.
Broader Implications
This development comes after a similar case in Kenya, where a high court halted a related health funding agreement after concerns were filed about the safety of Kenyans' health data.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral deals to boost openness and responsibility.
As per statements, 16 nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our country would supply the basic resources for scientific discovery without any assurance that the end products would be accessible to our population if a future pandemic arise."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were undermining frameworks already established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This system is designed to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our US partners on how future collaboration might be arranged in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it understood the government's concerns, but suggested that talks must proceed since a large portion of the country's HIV programmes relied on foreign aid.
"If technical issues arise, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
This impasse underscores the continuing challenges between receiving much-needed international aid and protecting national sovereignty in an ever more data-driven world.